This is what I call lazy analysis. If the investors in this company were solely here for COVID the stock would have crashed below 1 dollar on the 30th.
"Myriad of uncertanties" did not seem to be a problem when HC Wainright recommended this as a buy. There were no results for COVID when the buy recommendation came out. Nothing has materially changed in the science. The EINDs are still 80% efficacy.
The only thing that occurred was the dip on the 30th. Whoever looked at this simply said to themselves "penny stock" and did no further due diligence . No mention of HIV BLA, no mention of NASH, no mention of the cancer basket trial.
So I have to take this with a grain of salt and stick with my own DD.